Decoding the language of cells to design better therapies for patients.
The promise of CAR-T therapy is immense. Yet, the path from bench to bedside remains a high-risk gamble. Unpredictable and life-threatening toxicities like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are major barriers to its widespread adoption.
Q-Immune's mission is to solve this core challenge. We are building the critical "bench to bedside to bench" validation loop that the industry has been missing. Our platform combines high-throughput multiplex proteomics and AI to unlock a therapy’s functional blueprint, moving beyond traditional assays to capture the dynamic signaling networks that predict a therapy’s safety and efficacy. By translating this complex cellular language into actionable biosignatures, we are transforming CAR-T from a last resort into a predictable, safe, and widely accessible treatment for all.
OUR APPROACH
Predicting Therapeutic Performance from a Cell’s Functional Blueprint
The most significant barrier to the widespread adoption of next-generation cell therapies is not a lack of innovation, but a lack of predictability. Standard preclinical assays and in vitro models frequently fail to anticipate a therapy's true performance in patients, particularly for severe toxicities like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). This gap between preclinical promise and clinical reality creates immense financial risk for developers and logistical hurdles for hospitals.
Q-Immune’s platform is designed to close this gap. We generate the high-resolution, functional data needed to move beyond traditional assumptions. By directly measuring the dynamic protein interaction networks within living cells, our technology provides an unparalleled view into how design choices translate into a therapy's clinical behavior. This proprietary data fuels our predictive models, allowing us to generate a validated "biosignature" that accurately forecasts a therapy's safety and efficacy before it reaches the patient.
OUR TECHNOLOGY
QMI + AI
A Predictive Platform for Cellular Therapies
Our platform achieves its predictive capability through the strategic integration of our proprietary Quantitative Multiplex co-Immunoprecipitation (QMI) assay and an AI-driven analytical engine. The QMI assay provides a functional, mesoscale interrogation of native protein-protein interactions within living cells, generating the high-resolution dataset required for functional pathway analysis. This quantitative data is processed by our AI engine to establish a definitive, predictive Biosignature that correlates the therapy's intracellular signaling profile directly with clinical outcomes. By unifying molecular design with functional biological data, this system provides partners with the necessary certainty to quantitatively de-risk and accelerate the development timeline for next-generation cellular medicines.